CareDx, Inc
CDNA
株式のランク
#4445
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
株価
$67.25
最終同期: 2026-10-19
時価総額
$3.48B
変化（1日）
5.08%
変化（1年）
341.85%
国
US
取引 CareDx, Inc (CDNA)
カテゴリー
Healthcare
CareDx, Inc（CDNA）の発行済株式数
June 2026 時点の発行済株式数 51.47M
CareDx, Inc の最新の財務報告および株価によると、現在の発行済株式数は 51.47M です。December 2023 の終わりには、同社は 53.76M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
CareDx, Inc（CDNA）の発行済株式数の履歴（2012 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 51.47M | -2.47% |
| 2024 | 52.77M | -1.84% |
| 2023 | 53.76M | 0.83% |
| 2022 | 53.32M | 2.07% |
| 2021 | 52.24M | 12.39% |
| 2020 | 46.48M | 10.27% |
| 2019 | 42.15M | 18.27% |
| 2018 | 35.64M | 52.92% |
| 2017 | 23.31M | 41.28% |
| 2016 | 16.50M | 39.61% |
| 2015 | 11.82M | 103.17% |
| 2014 | 5.82M | -21.12% |
| 2013 | 7.37M | 0.00% |
| 2012 | 7.37M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 371.00M | 620.82% |
US
|
|
| 705.30M | 1,270.33% |
US
|
|
| 143.28M | 178.38% |
US
|
|
| - | - |
CN
|
|
| 282.00M | 447.90% |
US
|
